Join the 200th Anniversary Celebration

Original Article

A Founder Mutation as a Cause of Cerebral Cavernous Malformation in Hispanic Americans

Murat Günel, M.D., Issam A. Awad, M.D., Karin Finberg, B.S., John A. Anson, M.D., Gary K. Steinberg, M.D., Ph.D., H. Hunt Batjer, M.D., Thomas A. Kopitnik, M.D., Leslie Morrison, M.D., Steven L. Giannotta, M.D., Carol Nelson-Williams, B.S., and Richard P. Lifton, M.D., Ph.D.

N Engl J Med 1996; 334:946-951April 11, 1996

Abstract

Background

Cerebral cavernous malformation is a vascular disease of the brain causing headaches, seizures, and cerebral hemorrhage. Familial and sporadic cases are recognized, and a gene causing familial disease has been mapped to chromosome 7. Hispanic Americans have a higher prevalence of cavernous malformation than do other ethnic groups, raising the possibility that affected persons in this population have inherited the same mutation from a common ancestor.

Methods

We compared the segregation of genetic markers and clinical cases of cavernous malformation in Hispanic-American kindreds with familial disease; we also compared the alleles for markers linked to cavernous malformation in patients with familial and sporadic cases.

Results

All kindreds with familial disease showed linkage of cavernous malformation to a short segment of chromosome 7 (odds supporting linkage, 4×1010:1). Forty-seven affected members of 14 kindreds shared identical alleles for up to 15 markers linked to the cavernous-malformation gene, demonstrating that they had inherited the same mutation from a common ancestor. Ten patients with sporadic cases also shared these same alleles, indicating that they too had inherited the same mutation. Thirty-three asymptomatic carriers of the disease gene were identified, demonstrating the variability and age dependence of the development of symptoms and explaining the appearance of apparently sporadic cases.

Conclusions

Virtually all cases of familial and sporadic cavernous malformation among Hispanic Americans of Mexican descent are due to the inheritance of the same mutation from a common ancestor.

Media in This Article

Figure 3Identical 7q Haplotypes in Patients with Cavernous Malformation.
Figure 1Sagittal T1-Weighted (Panel A) and Axial T2-Weighted (Panel B) Magnetic Resonance Images Demonstrating the Typical Appearance of Cavernous Malformation.
Article

Cerebral cavernous malformation is a vascular disorder of the brain characterized by abnormal vascular spaces lined by a single layer of endothelium without intervening neural parenchyma or identifiable mature vessel-wall elements.1,2 There is almost always evidence of prior hemorrhage, characterized by the accumulation of hemosiderin. This disease was recognized as a common clinical entity after the advent of magnetic resonance imaging (MRI), which demonstrates a characteristic lesion of variable signal intensity surrounded by a dark ring attributable to hemosiderin (Figure 1AFigure 1Sagittal T1-Weighted (Panel A) and Axial T2-Weighted (Panel B) Magnetic Resonance Images Demonstrating the Typical Appearance of Cavernous Malformation. and Figure 1B).3,4 Before the introduction of MRI, patients with cavernous malformation were typically classified as having an idiopathic seizure disorder or an angiographically occult vascular malformation. Both MRI and autopsy studies suggest a prevalence of cavernous malformation of 0.5 percent, although the prevalence of symptomatic disease is much lower.5,6

Symptomatic disease typically begins in the third through fifth decades of life.5,7-9 Treatment ranges from therapy with antiepileptic drugs in patients with seizures to surgical excision of accessible lesions in patients with recurrent hemorrhage or intractable seizures.10-13

Although the pathogenesis of cavernous malformation is unknown, a familial predisposition has been recognized, with up to 55 percent of patients having an affected relative.14-23 Genetic linkage studies have recently mapped a gene causing cavernous malformation to a segment of the long arm of chromosome 7 (7q).24,25

Familial and sporadic cases are particularly evident among Hispanic Americans of Mexican descent.14,15,21-23 The disproportionate number of cases in this population raises the possibility that a common mutation inherited from a shared ancestor (a founder mutation) may be responsible for the disease. If identified, such a founder mutation would permit both the development of a highly specific genetic test for the disease and an assessment of whether apparently sporadic cases in this group are in fact genetic and due to the same mutation.

Methods

Patients

The study protocol was approved by the Human Investigation Committee at Yale University School of Medicine. Informed consent was obtained from the study participants. Twenty-two patients with cavernous malformation, who described themselves as Hispanic Americans, were identified from neurosurgical records at the University of New Mexico and Stanford University; two Hispanic-American kindreds affected by familial cavernous malformation were identified by the University of Texas Southwestern Medical School and the University of Southern California. Eleven of the index patients had surgically documented cavernous malformation, and 13 had diagnostic findings on MRI.

Detailed family trees were assembled, and family medical histories were obtained. The ancestors of 22 patients were from Mexico, and the origin of 2 families was uncertain. None of these families were known to be related to one another; tracing family trees to at least the great-grandparents of each index patient identified no ancestors shared by two or more kindreds.

Control Subjects

For the estimation of the allele frequencies, 16 Hispanic spouses of the index patients and 33 unrelated, healthy Hispanic volunteers recruited by the University of New Mexico (n = 19) and Stanford University (n = 14) served as controls. In addition, 62 independent chromosomes not linked to cavernous malformation in the study kindreds were used as controls. There were no significant differences in allele frequencies among these groups for any of the markers studied.

Genotyping and Analysis of Linkage and Linkage Disequilibrium

Genomic DNA was prepared from venous blood.26 Highly informative genetic markers on chromosome 7q were genotyped by the polymerase chain reaction.25 The genotypes were assessed independently by two investigators who were unaware of the subjects' status.

For the analysis of linkage, subjects with diagnostic findings on surgery or MRI were classified as affected. Asymptomatic subjects over the age of 20 with no history of seizures, headaches, or cerebral hemorrhage were classified as unaffected, whereas asymptomatic subjects 20 years of age or younger were classified as having an unknown phenotype. All phenotypes were assigned prospectively.

Linkage analysis27 was performed, with cavernous malformation specified as an autosomal dominant trait with a gene frequency of 0.001, penetrance of 80 percent, and prevalence of sporadic cases of 0.001.25 Changing the estimates of penetrance or the prevalence of sporadic cases had small effects on the lod score and did not affect the location of the mutant gene.

Haplotypes (the string of particular alleles for different markers present on individual chromosomes) were constructed on the basis of linkage within families. The likelihood of finding specific haplotypes by chance was calculated as the product of the allele frequencies on control chromosomes. The allele frequencies in the patients and controls and disease penetrances in different age groups were compared by the chi-square test.28 The ages of symptomatic and asymptomatic gene carriers were compared by a two-tailed t-test.28

We calculated Pexcess, an indicator of the degree of departure of marker-allele frequencies in patients from those found in controls, with the following equation:

Pexcess = (Ppatients - Pcontrols)/(1 - Pcontrols),

where Ppatients and Pcontrols denote the frequency of a particular allele on cavernous-malformation and control chromosomes, respectively.29,30

Results

One or more additional cases of cavernous malformation were identified among the relatives of 14 of the 24 index patients (58 percent) — a figure consistent with prior estimates for the familial form of the disease in Hispanic Americans.15 Thus, a total of 57 patients (31 female and 26 male) with a diagnosis of cavernous malformation were studied: 47 members of 14 kindreds with familial cavernous malformation and 10 patients with sporadic cases. The patients ranged in age from 2 to 69 years. Four symptomatic patients were given a diagnosis before the age of 10, 34 were given a diagnosis between the ages of 10 and 40, and initial symptoms developed in 9 patients after the age of 40. Ten patients were asymptomatic. Signs and symptoms included headache in 28 patients, seizure disorder in 22, and cerebral hemorrhage in 24.

Analysis of Linkage

Since prior studies have supported linkage of cavernous malformation to a large segment of 7q,24,25 we compared the segregation of genetic markers on 7q to the segregation of cavernous malformation in the 10 families with 2 or more living affected members. Analysis showed strong evidence favoring linkage of cavernous malformation to a segment of 7q in all families. For example, every affected member of Family 1 inherited allele 6 of locus D7S657, whereas none of the unaffected family members inherited this allele (Figure 2AFigure 2Linkage of Cavernous Malformation to Chromosome 7q.). Similar analyses can be performed in all families with this and additional markers. The odds of the observed linkage results' occurring by chance were calculated and compared with the likelihood of observing these results under the specified model of linkage (Figure 2B). In all 10 families combined, the odds favoring linkage to D7S657 with no recombination were 4×1010:1 (lod score, 10.6). Nearby markers, D7S492 and D7S479, did not completely cosegregate with the disease, which indicates that the disease gene was located in a 7-cM segment between D7S492 and D7S479. These findings are consistent with the hypothesis that all cases of cavernous malformation in these kindreds are due to a mutation in the same gene, but they provide no indication of whether the same or independent mutations cause the disease in different kindreds.

Evidence That All Familial Cases Are Due to the Same Mutant Chromosome

To assess the possibility that different kindreds with familial cavernous malformation inherited the same mutation from a common ancestor, we compared the alleles for markers closely linked to the cavernous-malformation gene in affected members of different kindreds (Figure 3Figure 3Identical 7q Haplotypes in Patients with Cavernous Malformation.). If all these families had independent mutations in the same gene, these mutations would have occurred on unrelated chromosomes; consequently, alleles of genetic markers linked to the disease gene would show no greater similarity to one another in different kindreds than expected by chance, and marker alleles and cavernous-malformation mutations would be said to be in linkage equilibrium. Alternatively, if different families had all inherited the identical mutation from a common ancestor, the alleles of markers closely linked to the disease gene would be identical to one another, since they would all have descended from the same ancestral chromosome. In this case, knowledge that a chromosome carries a mutation at the cavernous-malformation locus would be predictive of the genotype at a flanking locus, and these alleles would be said to be in linkage disequilibrium.

Analysis of marker D7S689, which showed no recombination with cavernous malformation in these families, revealed that 47 of 47 disease chromosomes from affected subjects of 14 kindreds with familial cavernous malformation carried allele 2 of this marker, as compared with only 4 of 98 chromosomes from Hispanic control subjects (P<0.001) (Figure 3). This finding provides strong evidence of linkage disequilibrium between cavernous malformation and this marker in these families and is corroborated by analysis of other markers tightly linked to the cavernous-malformation gene (Figure 3). The degree of linkage disequilibrium is expressed as Pexcess; this value is zero if the allele frequencies in patients and controls are identical, and 1.0 if every disease allele carries the same allele of a polymorphic marker. In this analysis, Pexcess was equal to or approximated 1.0 in the vicinity of D7S689 and diminished gradually toward zero in both directions from this location (Figure 3). This peak location is within the interval containing the cavernous-malformation gene that was defined by linkage analysis within families.

Analyses of haplotypes allow one to determine how long a piece of the original founder chromosome, in this case chromosome 7, is conserved among different subjects. Affected patients from 10 kindreds had identical haplotypes (identical alleles for each different genetic marker) over an interval of at least 22 cM, since the alleles for all 15 markers from D7S820 to D7S821 were identical. In unrelated Hispanic subjects, this haplotype would be expected to be found by chance on 1 chromosome in 7.8×1012. The finding of this same haplotype in members of 10 kindreds provides a strong indication that these shared segments were derived from a common ancestral chromosome.

Affected subjects from 4 other kindreds with familial cavernous malformation shared haplotypes with these 10 families over shorter segments, ranging from 16 to 1 cM. These shared haplotypes all included at least a portion of the interval containing the cavernous-malformation gene identified by linkage analysis. The likelihood of finding these haplotypes by chance ranges from 9.2×10-3 to 2.6×10-7. These findings indicate that the patients in all the families inherited the same cavernous-malformation mutation by descent from a common ancestor.

Penetrance of Symptomatic Disease

The identification of a conserved haplotype in kindreds with familial cavernous malformation provides an opportunity to determine the proportion of persons who have inherited the cavernous-malformation mutation who are clinically symptomatic (the penetrance of the trait). Sixty-eight members of families with two or more living affected members were screened for the conserved haplotype. Thirty-three asymptomatic subjects harboring the entire conserved haplotype spanning the interval from D7S492 to D7S479 were identified, including 10 subjects in whom the disease had been previously diagnosed by MRI. The mean (±SE) age of these subjects was significantly lower than that of symptomatic subjects (25±3.5 vs. 37±2.5 years, P = 0.004), suggesting that the asymptomatic subjects are at risk for symptomatic disease in the future.

From these data, age-specific penetrances of symptomatic disease can be estimated (Table 1Table 1Age Dependence of the Symptoms of Cavernous Malformation.). The prevalence of symptomatic disease varied significantly with age, being low until the age of 20 (27 percent) and increasing to 66 percent after the age of 20 (P = 0.002). The prevalence of symptomatic disease never increased above 76 percent in any decade, indicating that penetrance of the disease is age-dependent and less than 100 percent in all age groups.

Evidence That Sporadic Cases Are Also Genetic

The finding that all patients with familial disease had inherited the same mutation from a common ancestor, coupled with the knowledge that disease penetrance was incomplete, raised the question of whether Hispanic patients with apparently sporadic cases of cavernous malformation may have inherited the same mutation. To test this possibility, we determined the chromosome 7q genotypes and haplotypes of 10 patients with sporadic cavernous malformation. Eight of these patients had the same long haplotypes as patients with familial disease, which extended 12 to 30 cM and included identical alleles for 10 to 21 markers that span the location of the cavernous-malformation gene; the likelihoods of these haplotypes' occurring by chance range from 2×10-13 to 2.4×10-6. The remaining two kindreds shared a portion of the conserved haplotype within the interval containing the cavernous-malformation gene, with likelihoods that these are chance findings of 2.4×10-3 and 0.14. These results indicate that virtually all sporadic cases in this group were genetic and due to the inheritance of the same mutation as was inherited by patients with familial disease.

Refined Location of the Cavernous-Malformation Gene

Knowledge of a founder cavernous-malformation mutation in this population can be used to refine the location of the disease gene. The founder chromosome had one specific allele at each marker locus. The span of this ancestral haplotype has been reduced in subsequent generations by recombination, with ancestral alleles for markers more closely linked to the mutation being retained and more distant marker alleles being exchanged for alleles that are representative of the general population. Consequently, identification of the minimal set of marker alleles shared by all patients who inherited the founder mutation can be used to define the location of the disease gene; this approach, called disequilibrium mapping, takes advantage of many more meiotic events than can be observed in individual families. In patients with familial disease, all disease chromosomes had the same alleles for markers D7S646, D7S558, and D7S689. These findings strongly suggest that the cavernous-malformation gene lies very near these loci, refining the position of the mutant gene considerably from that obtained by meiotic mapping in individual kindreds.

Discussion

Although cavernous malformation has been recognized as an autosomal dominant trait in some families, 50 percent of cases have been classified as sporadic.15-22 In the present study, virtually all cases in Hispanic Americans of Mexican descent, including apparently sporadic cases, could be attributed to inheritance of the same mutation from a common ancestor. The apparent paradox of sporadic cases' being due to the same mutation as familial cases can be explained by incomplete penetrance, with some carriers remaining asymptomatic. The only argument against this interpretation is the finding of one patient with a sporadic case who harbored only a small segment containing two marker alleles of the conserved haplotype in the linked interval. This patient could have either the same mutation or an independent mutation that occurred by chance on a chromosome with these alleles. This issue will be definitively resolved by the identification of the common cavernous-malformation mutation in Hispanic Americans.

Meiotic mapping within families localized the cavernous-malformation gene to a 7-cM interval in Hispanic Americans, and disequilibrium mapping refined the location of the gene within this interval to a much smaller segment near loci D7S646, D7S558, and D7S689, greatly aiding the search for the underlying mutant gene. This interval can be excluded as the position of the cavernous-malformation gene in several non-Hispanic kindreds25 (and unpublished data), indicating that in at least some of these kindreds the disease is due to a mutation at other loci.

The long length of the conserved haplotype in many of the families studied suggests that in some cases the common ancestor with cavernous malformation may have been in a relatively recent generation. This possibility seems surprising given that the families were from diverse geographic locations and that no blood relationships were found between different kindreds, but it may reflect the relatively recent migration of a founder from Mexico to the United States. If so, some patients with cavernous malformation who live in Mexico might prove to share very small segments of the ancestral haplotype, permitting very precise mapping of the cavernous-malformation gene, as has been accomplished for several other diseases with founder mutations.29,30

The present findings have implications for the genetic diagnosis of cavernous malformation in Hispanic persons. To date, definitive diagnosis has relied on characteristic findings on MRI or surgery. Our demonstration that the disease is commonly due to the inheritance of a founder mutation in this ethnic group indicates that genetic testing can be used for the preclinical diagnosis of cavernous malformation. Moreover, once the disease-causing mutation in this population has been identified, a single direct test of high sensitivity and specificity will be available and applicable to this group. The advantages and drawbacks of such testing will have to be carefully considered in each case.

The ability to identify carriers of cavernous-malformation mutations also provides the potential to recognize affected subjects in other diagnostic groups. For example, 20 percent of patients with intractable temporal-lobe epilepsy harbor intracranial mass lesions; cavernous malformation accounts for one fourth of these lesions.32 If a simple genetic test becomes available, it may be used to identify patients with cavernous malformation among Hispanic Americans with intractable epilepsy.

Finally, these findings have implications for the pathogenesis of cavernous malformation in non-Hispanics, among whom familial and sporadic cases have been recognized.1,16-20 The finding that virtually all sporadic cases among Hispanic Americans are in fact genetic raises the possibility that many apparently sporadic cases in non-Hispanic patients will also prove to be genetic. The present findings provide the framework for a unified understanding of the pathogenesis of this disease.

Dr. Günel is the recipient of a scholarship from the American College of Surgeons. Dr. Lifton is an investigator of the Howard Hughes Medical Institute.

We are indebted to the patients and their families for their participation in the study, and to Debra Garcia, R.N., Teresa Bell, R.N., Retha Jane Woods, R.N., Dawn Fishback, P.A.-C., Evangeline Thompson, R.N., and Kathy McNamara, R.N., for their help in patient recruitment.

Source Information

From the Howard Hughes Medical Institute (M.G., K.F., C.N.-W., R.P.L.), the Section of Neurosurgery (M.G., I.A.A.), and the Departments of Cell Biology (M.G.) and Medicine and Genetics (C.N.-W., R.P.L.), Yale University, New Haven, Conn.; the Departments of Neurosurgery (J.A.A.) and Neurology (L.M.), University of New Mexico, Albuquerque; the Department of Neurosurgery, Stanford University, Palo Alto, Calif. (G.K.S.); the Department of Neurosurgery, Northwestern University, Chicago (H.H.B.); the Department of Neurosurgery, University of Texas Southwestern Medical Center, Dallas (T.A.K.); and the Department of Neurosurgery, University of Southern California, Los Angeles (S.L.G.).

Address reprint requests to Dr. Lifton at Yale University School of Medicine, Howard Hughes Medical Institute, Boyer Center for Molecular Medicine, 295 Congress Ave., New Haven, CT 06510.

References

References

  1. 1

    Russell DS, Rubinstein LJ. Pathology of tumours of the nervous system. 5th ed. Baltimore: Williams & Wilkins, 1989:730-6.

  2. 2

    Johnson P, Wascher T, Golfinos J, Spetzler R. Definition and pathological features. In: Awad I, Barrow D, eds. Cavernous malformations. Park Ridge, Ill.: American Association of Neurological Surgeons Press, 1993:1-11.

  3. 3

    Perl J, Ross J. Diagnostic imaging of cavernous malformations. In: Awad I, Barrow D, eds. Cavernous malformations. Park Ridge, Ill.: American Association of Neurological Surgeons Press, 1993:37-48.

  4. 4

    Rigamonti D, Drayer BP, Johnson PC, Hadley MN, Zabramski J, Spetzler RF. The MRI appearance of cavernous malformations (angiomas). J Neurosurg 1987;67:518-524
    CrossRef | Web of Science | Medline

  5. 5

    Del Curling O Jr, Kelly DL Jr, Elster AD, Craven TE. An analysis of the natural history of cavernous angiomas. J Neurosurg 1991;75:702-708
    CrossRef | Web of Science | Medline

  6. 6

    Otten P, Pizzolato GP, Rilliet B, Berney J. A propos de 131 cas d'angiomes caverneux (cavernomes) du S.N.C., repérés par l'analyse rétrospective de 24 535 autopsies. Neurochirurgie 1989;35:82-83
    Web of Science | Medline

  7. 7

    Hsu F, Rigamonti D, Huhn SL. Epidemiology of cavernous malformations. In: Awad I, Barrow D, eds. Cavernous malformations. Park Ridge, Ill.: American Association of Neurological Surgeons Press, 1993:13-23.

  8. 8

    Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. J Neurosurg 1991;75:709-714
    CrossRef | Web of Science | Medline

  9. 9

    Barrow D, Krisht A. Cavernous malformations and hemorrhage. In: Awad I, Barrow D, eds. Cavernous malformations. Park Ridge, Ill.: American Association of Neurological Surgeons Press, 1993:65-80.

  10. 10

    Barrow D, Awad I. Conceptual overview and management strategies. In: Awad I, Barrow D, eds. Cavernous malformations. Park Ridge, Ill.: American Association of Neurological Surgeons Press, 1993:205-13.

  11. 11

    Robinson JR Jr, Awad IA, Magdinec M, Paranandi L. Factors predisposing to clinical disability in patients with cavernous malformations of the brain. Neurosurgery 1993;32:730-735
    CrossRef | Web of Science | Medline

  12. 12

    Huhn S, Rigamonti D, Hsu F. Indications for surgical intervention. In: Awad I, Barrow D, eds. Cavernous malformations. Park Ridge, Ill.: American Association of Neurological Surgeons Press, 1993:87-99.

  13. 13

    Ojemann RG, Crowell RM, Ogilvy CS. Management of cranial and spinal cavernous angiomas. Clin Neurosurg 1993;40:98-123
    Medline

  14. 14

    Hayman LA, Evans RA, Ferrell RE, Fahr LM, Ostrow P, Riccardi VM. Familial cavernous angiomas: natural history and genetic study over a 5-year period. Am J Med Genet 1982;11:147-160
    CrossRef | Web of Science | Medline

  15. 15

    Rigamonti D, Hadley MN, Drayer BP, et al. Cerebral cavernous malformations: incidence and familial occurrence. N Engl J Med 1988;319:343-347
    Full Text | Web of Science | Medline

  16. 16

    Steichen-Gersdorf E, Felber S, Fuchs W, Russeger L, Twerdy K. Familial cavernous angiomas of the brain: observations in a four generation family. Eur J Pediatr 1992;151:861-863
    CrossRef | Web of Science | Medline

  17. 17

    Clark JV. Familial occurrence of cavernous angiomata of the brain. J Neurol Neurosurg Psychiatry 1970;33:871-876
    CrossRef | Web of Science | Medline

  18. 18

    Dobyns WB, Michels VV, Groover RV, et al. Familial cavernous malformations of the central nervous system and retina. Ann Neurol 1987;21:578-583
    CrossRef | Web of Science | Medline

  19. 19

    Gangemi M, Maiuri F, Donati P, Cinalli G, DeCaro M, Sigona L. Familial cerebral cavernous angiomas. Neurol Res 1990;12:131-136
    Medline

  20. 20

    Kidd HA, Cumings JN. Cerebral angiomata in an Icelandic family. Lancet 1947;1:747-748
    CrossRef | Medline

  21. 21

    Bicknell JM, Carlow TJ, Kornfeld M, Stovring J, Turner P. Familial cavernous angiomas. Arch Neurol 1978;35:746-749
    Web of Science | Medline

  22. 22

    Mason I, Aase JM, Orrison WW, Wicks JD, Seigel RS, Bicknell JM. Familial cavernous angiomas of the brain in an Hispanic family. Neurology 1988;38:324-326
    Web of Science | Medline

  23. 23

    Zabramski JM, Wascher TM, Spetzler RF, et al. The natural history of familial cavernous malformations: results of an ongoing study. J Neurosurg 1994;80:422-432
    CrossRef | Web of Science | Medline

  24. 24

    Dubovsky J, Zabramski JM, Kurth J, et al. A gene responsible for cavernous malformations of the brain maps to chromosome 7q. Hum Mol Genet 1995;4:453-458
    CrossRef | Web of Science | Medline

  25. 25

    Gunel M, Awad IA, Anson J, Lifton RP. Mapping a gene causing cerebral cavernous malformation to 7q11.2-q21. Proc Natl Acad Sci U S A 1995;92:6620-6624
    CrossRef | Web of Science | Medline

  26. 26

    Bell GI, Karam JH, Rutter WJ. Polymorphic DNA region adjacent to the 5' end of the human insulin gene. Proc Natl Acad Sci U S A 1981;78:5759-5763
    CrossRef | Web of Science | Medline

  27. 27

    Lathrop GM, Lalouel JM, Julier C, Ott J. Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci U S A 1984;81:3443-3446
    CrossRef | Web of Science | Medline

  28. 28

    Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford, England: Blackwell Scientific, 1987.

  29. 29

    Hastbacka J, de la Chapelle A, Kaitila I, Sistonen P, Weaver A, Lander E. Linkage disequilibrium mapping in isolated founder populations: diastrophic dysplasia in Finland. Nat Genet 1992;2:204-211[Erratum, Nat Genet 1992;2:343.]
    CrossRef | Web of Science | Medline

  30. 30

    Hastbacka J, de la Chapelle A, Mahtani MM, et al. The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium mapping. Cell 1994;78:1073-1087
    CrossRef | Web of Science | Medline

  31. 31

    Murray JC, Buetow KH, Weber JL, et al. A comprehensive human linkage map with centimorgan density. Science 1994;265:2049-2054
    CrossRef | Web of Science | Medline

  32. 32

    Spencer DD, Spencer SS, Mattson RH, Williamson PD. Intracerebral masses in patients with intractable partial epilepsy. Neurology 1984;34:432-436
    Web of Science | Medline

Citing Articles (70)

Citing Articles

  1. 1

    Daniel D. Cavalcanti, M. Yashar S. Kalani, Nikolay L. Martirosyan, Justin Eales, Robert F. Spetzler, Mark C. Preul. (2011) Cerebral cavernous malformations: from genes to proteins to disease. Journal of Neurosurgery1-11
    CrossRef

  2. 2

    Daniel L Barrow, Albert J Schuette. (2011) Cavernous Malformations: A Paradigm for Progress. Neurosurgery 69, 27-41
    CrossRef

  3. 3

    Gamze Tanriover, Berna Sozen, Murat Gunel, Necdet Demir. (2011) CCM2 expression during prenatal development and adult human neocortex. International Journal of Developmental Neuroscience 29:5, 509-514
    CrossRef

  4. 4

    Carol J. Gallione, Ann Solatycki, Issam A. Awad, James L. Weber, Douglas A. Marchuk. (2011) A founder mutation in the Ashkenazi Jewish population affecting messenger RNA splicing of the CCM2 gene causes cerebral cavernous malformations. Genetics in Medicine 13:7, 662-666
    CrossRef

  5. 5

    Helen Kim, Ludmila Pawlikowska, William L. Young. 2011. Genetics and Vascular Biology of Brain Vascular Malformations. , 169-186.
    CrossRef

  6. 6

    Carlos S. Kase, Steven M. Greenberg, J.P. Mohr, Louis R. Caplan. 2011. Intracerebral Hemorrhage. , 531-588.
    CrossRef

  7. 7

    Yoo Jin Hong, Tae-Sub Chung, Sang Hyun Suh, Chul Hwan Park, Geetanjali Tomar, Kwon Duk Seo, Keung Sik Kim, In Kook Park. (2010) The angioarchitectural factors of the cerebral developmental venous anomaly; can they be the causes of concurrent sporadic cavernous malformation?. Neuroradiology 52:10, 883-891
    CrossRef

  8. 8

    Chad W. Washington, Kathleen E. McCoy, Gregory J. Zipfel. (2010) Update on the natural history of cavernous malformations and factors predicting aggressive clinical presentation. Neurosurgical FOCUS 29:3, E7
    CrossRef

  9. 9

    Edward R. Smith, R. Michael Scott. (2010) Cavernous Malformations. Neurosurgery Clinics of North America 21:3, 483-490
    CrossRef

  10. 10

    Florence Riant, Francoise Bergametti, Xavier Ayrignac, Gwenola Boulday, Elisabeth Tournier-Lasserve. (2010) Recent insights into cerebral cavernous malformations: the molecular genetics of CCM. FEBS Journal 277:5, 1070-1075
    CrossRef

  11. 11

    T.A. Petersen, L.A. Morrison, R.M. Schrader, B.L. Hart. (2010) Familial versus Sporadic Cavernous Malformations: Differences in Developmental Venous Anomaly Association and Lesion Phenotype. American Journal of Neuroradiology 31:2, 377-382
    CrossRef

  12. 12

    C. Graeni, F. Stepper, M. Sturzenegger, A. Merlo, D. J. Verlaan, F. Andermann, C. R. Baumann, F. Bonassin, D. Georgiadis, R. W. Baumgartner, G. A. Rouleau, A. M. Siegel. (2010) Inherited cavernous malformations of the central nervous system: clinical and genetic features in 19 Swiss families. Neurosurgical Review 33:1, 47-51
    CrossRef

  13. 13

    Sachin Batra, Doris Lin, Pablo F. Recinos, Jun Zhang, Daniele Rigamonti. (2009) Cavernous malformations: natural history, diagnosis and treatment. Nature Reviews Neurology 5:12, 659-670
    CrossRef

  14. 14

    Azadeh Ebrahimi, Masoud Etemadifar, Pooneh M. Ardestani, Amir H. Maghzi, Stephen Jaffe, Hossein Nejadnik. (2009) Cavernous angioma: a clinical study of 35 cases with review of the literature. Neurological Research 31:8, 785-793
    CrossRef

  15. 15

    Milena Cau, Mario Loi, Maurizio Melis, Rita Congiu, Alberto Loi, Cristiana Meloni, Marianna Serrenti, Maria Addis, Maria Antonietta Melis. (2009) C329X in KRIT1 is a founder mutation among CCM patients in Sardinia. European Journal of Medical Genetics 52:5, 344-348
    CrossRef

  16. 16

    R. Rocamora, I. Mader, J. Zentner, A. Schulze-Bonhage. (2009) Epilepsy surgery in patients with multiple cerebral cavernous malformations. Seizure 18:4, 241-245
    CrossRef

  17. 17

    Silvana Penco, Rachele Ratti, Elena Bianchi, Alberto Citterio, Maria Cristina Patrosso, Alessandro Marocchi, Laura Tassi, Alessandro La Camera, Massimo Collice. (2009) Molecular screening test in familial forms of cerebral cavernous malformation: the impact of the Multiplex Ligation-dependent Probe Amplification approach. Journal of Neurosurgery 110:5, 929-934
    CrossRef

  18. 18

    Steven W. Hwang, Rolf M. Pfannl, Julian K. Wu. (2009) Convexity dural cavernous malformation with intradural and extradural extension mimicking a meningioma: a case report. Acta Neurochirurgica 151:1, 79-83
    CrossRef

  19. 19

    Seung-Tae Lee, Ki-Whan Choi, Hyung-Tae Yeo, Jong-Won Kim, Chang-Seok Ki, Young-Dae Cho. (2008) Identification of an Arg35X mutation in the PDCD10 gene in a patient with cerebral and multiple spinal cavernous malformations. Journal of the Neurological Sciences 267:1-2, 177-181
    CrossRef

  20. 20

    Gamze Tanriover, Arianne J. Boylan, Michael L. DiLuna, Katie L. Pricola, Angeliki Louvi, Murat Gunel. (2008) PDCD10, THE GENE MUTATED IN CEREBRAL CAVERNOUS MALFORMATION 3, IS EXPRESSED IN THE NEUROVASCULAR UNIT. Neurosurgery 62:4, 930-938
    CrossRef

  21. 21

    Mei-Hua Hu, Chieh-Tsai Wu, Kuang-Lin Lin, Alex Mun-Ching Wong, Shih-Ming Jung, Chang-Teng Wu, Shao-Hsuan Hsia. (2008) Intramedullary spinal arteriovenous malformation in a boy of familial cerebral cavernous hemangioma. Child's Nervous System 24:3, 393-396
    CrossRef

  22. 22

    YuZhen Tan, Yao Zhao, HaiJie Wang, LiangFu Zhou, Ying Mao, Rui Liu, Jia Shu, YongFei Wang. (2008) Effects of vascular endothelial growth factor on angiogenesis of the endothelial cells isolated from cavernous malformations. Chinese Science Bulletin 53:3, 370-376
    CrossRef

  23. 23

    P. Labauge, F. Parker, F. Chapon, E. Tournier-Lasserve. (2008) Cavernomi del sistema nervoso centrale. EMC - Neurologia 8:2, 1-7
    CrossRef

  24. 24

    Thomas Kopitnik, Debra Steele. (2007) Commentary. Surgical Neurology 68:5, 499-499
    CrossRef

  25. 25

    F. Ahlhelm, T. Hagen, G. Schulte-Altedorneburg, I. Grunwald, W. Reith, C. Roth. (2007) Kavernöse Malformationen. Der Radiologe 47:10, 863-867
    CrossRef

  26. 26

    Fernando Gianfrancesco, Milena Cannella, Tiziana Martino, Vittorio Maglione, Teresa Esposito, Gualtiero Innocenzi, Emilia Vitale, Christina L. Liquori, Douglas A. Marchuk, Ferdinando Squitieri. (2007) Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 144B:5, 691-695
    CrossRef

  27. 27

    B.J. Zlotoff, R.H. Bang, R.S. Padilla, L. Morrison. (2007) Cutaneous angiokeratoma and venous malformations in a Hispanic-American patient with cerebral cavernous malformations. British Journal of Dermatology 157:1, 210-212
    CrossRef

  28. 28

    Pierre Labauge, Christian Denier, Francoise Bergametti, Elisabeth Tournier-Lasserve. (2007) Genetics of cavernous angiomas. The Lancet Neurology 6:3, 237-244
    CrossRef

  29. 29

    Christian Denier, Pierre Labauge, Françoise Bergametti, Florence Marchelli, Florence Riant, Minh Arnoult, Jacqueline Maciazek, Eric Vicaut, Laurent Brunereau, Elisabeth Tournier-Lasserve, . (2006) Genotype-phenotype correlations in cerebral cavernous malformations patients. Annals of Neurology 60:5, 550-556
    CrossRef

  30. 30

    Stefan A. Mindea, Benson P. Yang, Robert Shenkar, Bernard Bendok, H. Hunt Batjer, Issam A. Awad. (2006) Cerebral cavernous malformations: clinical insights from genetic studies. Neurosurgical FOCUS 21:1, 1-7
    CrossRef

  31. 31

    Shervin R. Dashti, Alan Hoffer, Yin C. Hu, Warren R. Selman. (2006) Molecular genetics of familial cerebral cavernous malformations. Neurosurgical FOCUS 21:1, 1-5
    CrossRef

  32. 32

    James E. Conway, Daniele Rigamonti. (2006) Cavernous Malformations: A Review and Current Controversies. Neurosurgery Quarterly 16:1, 15-23
    CrossRef

  33. 33

    Aaron A. Cohen-Gadol, Jeffrey T. Jacob, Diane A. Edwards, William E. Krauss. (2006) Coexistence of intracranial and spinal cavernous malformations: a study of prevalence and natural history. Journal of Neurosurgery 104:3, 376-381
    CrossRef

  34. 34

    Nicholas W. Plummer, Jon S. Zawistowski, Douglas A. Marchuk. (2005) Genetics of cerebral cavernous malformations. Current Neurology and Neuroscience Reports 5:5, 391-396
    CrossRef

  35. 35

    Deniz Konya, ??zlem Yldrm, ??zlem Kurtkaya, Kaya Kl??, Peter McL. Black, M Necmettin Pamir, T??rker Kl??. (2005) Testing the Angiogenic Potential of Cerebrovascular Malformations by Use of a Rat Cornea Model: Usefulness and Novel Assessment of Changes over Time. Neurosurgery 56:6, 1339-1346
    CrossRef

  36. 36

    Masamitsu Abe, Kenji Fukudome, Yasuo Sugita, Tsuyoshi Oishi, Kazuo Tabuchi, Teruaki Kawano. (2005) Thrombus and encapsulated hematoma in cerebral cavernous malformations. Acta Neuropathologica 109:5, 503-509
    CrossRef

  37. 37

    A. M. Siegel, H. Bertalanffy, J. J. Dichgans, C. E. Elger, H. Hopf, N. Hopf, M. Keidel, A. Kleider, G. Nowak, R. A. Pfeiffer, J. Schramm, S. Spuck, H. Stefan, U. Sure, C. R. Baumann, G. A. Rouleau, D. J. Verlaan, E. Andermann, F. Andermann. (2005) Familire Kavernome des Zentralnervensystems. Der Nervenarzt 76:2, 175-180
    CrossRef

  38. 38

    Michael T. Lawton, G Edward Vates, Alfredo Quiñones-Hinojosa, William C. McDonald, Douglas A. Marchuk, William L. Young. (2004) Giant Infiltrative Cavernous Malformation: Clinical Presentation, Intervention, and Genetic Analysis: Case Report. Neurosurgery 55:4, 979-980
    CrossRef

  39. 39

    Kelley M. Dodson, Aristides Sismanis, Walter E. Nance. (2004) Superficial siderosis: A potentially important cause of genetic as well as non-genetic deafness. American Journal of Medical Genetics 130A:1, 22-25
    CrossRef

  40. 40

    Judith Gault, Hemant Sarin, Nabil A. Awadallah, Robert Shenkar, Issam A. Awad. (2004) Pathobiology of Human Cerebrovascular Malformations: Basic Mechanisms and Clinical Relevance. Neurosurgery 55:1, 1-17
    CrossRef

  41. 41

    Christian Denier, Pierre Labauge, Laurent Brunereau, Florence Cav-Riant, Florence Marchelli, Minh Arnoult, Michaelle Cecillon, Jacqueline Maciazek, Anne Joutel, Elisabeth Tournier-Lasserve, , . (2004) Clinical features of cerebral cavernous malformations patients withKRIT1 mutations. Annals of Neurology 55:2, 213-220
    CrossRef

  42. 42

    Carlos S. Kase, J.P. Mohr, Louis R. Caplan. 2004. Intracerebral Hemorrhage. , 327-376.
    CrossRef

  43. 43

    Andrew T. Parsa, Robert A. Solomon. 2004. Vascular Malformations of the Brain. , 1337-1367.
    CrossRef

  44. 44

    Adetokunbo A. Oyelese, Ian G. Fleetwood, Gary K. Steinberg. 2004. Cavernous Malformations and Venous Anomalies: Natural History and Surgical Management. , 1369-1391.
    CrossRef

  45. 45

    Wouter I. Schievink, Mary Riedinger, Tajinder K. Jhutty, Paul Simon. (2004) Racial Disparities in Subarachnoid Hemorrhage Mortality: Los Angeles County, California, 1985&ndash;1998. Neuroepidemiology 23:6, 299-305
    CrossRef

  46. 46

    Gelareh Zadeh, Abhijit Guha. (2003) Angiogenesis in Nervous System Disorders. Neurosurgery1362-1376
    CrossRef

  47. 47

    Anne Williamson, Peter R. Patrylo, Sunghoon Lee, Dennis D. Spencer. (2003) Physiology of Human Cortical Neurons Adjacent to Cavernous Malformations and Tumors. Epilepsia 44:11, 1413-1419
    CrossRef

  48. 48

    Richard C. Anderson, E. Sander Connolly, Koray Ozduman, Maxwell S.H. Laurans, Murat Gunel, Alexander Khandji, Phyllis L. Faust, Michael B. Sisti. (2003) Clinicopathological Review: Giant Intraventricular Cavernous Malformation. Neurosurgery 53:2, 374-379
    CrossRef

  49. 49

    Maxwell S. H. Laurans, Michael L. DiLuna, Dana Shin, Faheem Niazi, Jennifer R. Voorhees, Carol Nelson-Williams, Eric W. Johnson, Adrian M. Siegel, Gary K. Steinberg, Michel J. Berg, R. Michael Scott, Gioacchino Tedeschi, T. Peter Enevoldson, John Anson, Guy A. Rouleau, Christopher Ogilvy, Issam A. Awad, Richard P. Lifton, Murat Gunel. (2003) Mutational analysis of 206 families with cavernous malformations. Journal of Neurosurgery 99:1, 38-43
    CrossRef

  50. 50

    Prithvi Narayan, Daniel L. Barrow. (2003) Intramedullary spinal cavernous malformation following spinal irradiation. Journal of Neurosurgery: Spine 98:1, 68-72
    CrossRef

  51. 51

    D WOO, J BRODERICK. (2002) Spontaneous intracerebral hemorrhage: epidemiology and clinical presentation. Neurosurgery Clinics of North America 13:3, 265-279
    CrossRef

  52. 52

    Verne S. Caviness. (2002) Developmental vasculopathies as manifestations of dysregulated histogenetic signal transduction pathways. Current Opinion in Neurology 15:2, 127-131
    CrossRef

  53. 53

    Dong-Hui Chen, Hillary P. Lipe, Zhen Qin, Thomas D. Bird. (2002) Cerebral cavernous malformation: novel mutation in a Chinese family and evidence for heterogeneity. Journal of the Neurological Sciences 196:1-2, 91-96
    CrossRef

  54. 54

    Ulrich Sure, Nick Butz, Jürgen Schlegel, Adrian M. Siegel, Jörg P. Wakat, Hans D. Mennel, Siegfried Bien, Helmut Bertalanffy. (2001) Endothelial proliferation, neoangiogenesis, and potential de novo generation of cerebrovascular malformations. Journal of Neurosurgery 94:6, 972-977
    CrossRef

  55. 55

    Corstiaan C. Breugem, Chantal M. A. M. van der Horst, Raoul C. M. Hennekam. (2001) Progress toward Understanding Vascular Malformations. Plastic and Reconstructive Surgery 107:6, 1509-1523
    CrossRef

  56. 56

    Richard E. Clatterbuck, John L. Moriarity, Ilhan Elmaci, Roland R. Lee, Steven N. Breiter, Daniele Rigamonti. (2000) Dynamic nature of cavernous malformations: a prospective magnetic resonance imaging study with volumetric analysis. Journal of Neurosurgery 93:6, 981-986
    CrossRef

  57. 57

    Roberto C. Heros, Jacques J. Morcos. (2000) Cerebrovascular Surgery: Past, Present, and Future. Neurosurgery 47:5, 1007-1033
    CrossRef

  58. 58

    Harel Deutsch, George I. Jallo, Alina Faktorovich, Fred Epstein. (2000) Spinal intramedullary cavernoma: clinical presentation and surgical outcome. Journal of Neurosurgery: Spine 93:1, 65-70
    CrossRef

  59. 59

    Miguel Lucas, Francisca Solano, Mara D. Zayas, Jose M. Garca-Moreno, Miguel A. Gamero, Alzenira F. Costa, Guillermo Izquierdo. (2000) Spanish families with cerebral cavernous angioma do not bear 742C?T Hispanic American mutation of theKRIT1 gene. Annals of Neurology 47:6, 836-836
    CrossRef

  60. 60

    John H. Wong, Issam A. Awad, Jung H. Kim. (2000) Ultrastructural Pathological Features of Cerebrovascular Malformations: A Preliminary Report. Neurosurgery 46:6, 1454-1459
    CrossRef

  61. 61

    Jun Zhang, Richard E. Clatterbuck, Daniele Rigamonti, Harry C. Dietz. (2000) Mutations in KRIT1 in Familial Cerebral Cavernous Malformations. Neurosurgery 46:5, 1272-1279
    CrossRef

  62. 62

    Joshua Rosenow, Ahmed Rawanduzy, Imre Weitzner, William T. Couldwell. (2000) Type IV Spinal Arteriovenous Malformation in Association with Familial Pulmonary Vascular Malformations: Case Report. Neurosurgery 46:5, 1240-1245
    CrossRef

  63. 63

    A. Meiner, R. Faber, L.-C. Horn, H. Reichenbach, U. G. Froster. (1999) Prenatal detection of a giant bilateral thoracic vascular lesion: prognostic evaluation and genetic aspects. Prenatal Diagnosis 19:6, 583-586
    CrossRef

  64. 64

    Pierre Labauge, Odile Enjolras, Jean-Jacques Bonerandi, Sophie Laberge, Michel Dandurand, Jean-Marie Joujoux, Elisabeth Tournier-Lasserve. (1999) An association between autosomal dominant cerebral cavernomas and a distinctive hyperkeratotic cutaneous vascular malformation in 4 families. Annals of Neurology 45:2, 250-254
    CrossRef

  65. 65

    Saleem I. Abdulrauf, Mehmet Y. Kaynar, Issam A. Awad. (1999) A Comparison of the Clinical Profile of Cavernous Malformations with and without Associated Venous Malformations. Neurosurgery 44:1, 41-46
    CrossRef

  66. 66

    Pierre Labauge, Sophie Laberge, L Brunereau, C Levy, Elisabeth Tournier-Lasserve. (1998) Hereditary cerebral cavernous angiomas: clinical and genetic features in 57 French families. The Lancet 352:9144, 1892-1897
    CrossRef

  67. 67

    (1998) Radiation-Induced Cavernous Malformation. Journal of Neurosurgery 89:1,
    CrossRef

  68. 68

    Paul W. Detwiler, Randall W. Porter, Joseph M. Zabramski, Robert F. Spetzler. (1997) De novo formation of a central nervous system cavernous malformation: implications for predicting risk of hemorrhage. Journal of Neurosurgery 87:4, 629-632
    CrossRef

  69. 69

    Eugenio Pozzati, Felice Giangaspero, Federica Marliani, Nicola Acciarri. (1996) Occult Cerebrovascular Malformations after Irradiation. Neurosurgery 39:4, 677-684
    CrossRef

  70. 70

    Murat Günel, Richard P. Lifton. (1996) Counting strokes. Nature Genetics 13:4, 384-385
    CrossRef